CHARLES BRAMLET: Open Payments
NPI 1457438947 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$554 in 27 payments from 13 companies in 2025. Trend: 2023 $586 · 2024 $565 · 2025 $554
Food & beverage: $554
| Company | Payments | Amount |
|---|---|---|
| Noven Therapeutics, LLC | 9 | $188 |
| Alkermes, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| ABBVIE INC. | 2 | $37 |
| Corium, LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
Products named: Xelstrym, ARISTADA, TRINTELLIX, FANAPT, VRAYLAR, Azstarys, REXULTI, Relexxii.
Industry payments across LA — which companies pay providers there.
